Featured Research

from universities, journals, and other organizations

Getting off tract: Polyglutamine disease involves other regions of protein

Date:
September 23, 2010
Source:
Cell Press
Summary:
Many genes code for proteins that have a "polyglutamine tract," several glutamine amino acid residues in a row. Nine inherited neurodegenerative diseases, including Huntington's disease and spinocerebellar ataxia type 1 (SCA1), are associated with mutations that cause abnormally long polyglutamine tracts. One theory suggests that accumulation of proteins with extra glutamines damages and kills neurons. However, there is evidence that glutamine tract expansion alone is not sufficient to cause disease.

Many genes code for proteins that have a "polyglutamine tract," several glutamine amino acid residues in a row. Nine inherited neurodegenerative diseases, including Huntington's disease and spinocerebellar ataxia type 1 (SCA1), are associated with mutations that cause abnormally long polyglutamine tracts. One theory suggests that accumulation of proteins with extra glutamines damages and kills neurons. However, there is evidence that glutamine tract expansion alone is not sufficient to cause disease.

Related Articles


Now, new research published by Cell Press in the September 23 issue of the journal Neuron, reveals that initiation and progression of SCA1 are distinct from cell death and that changes outside of the polyglutamine tract are critical for disease pathogenesis. These findings could help to direct future therapeutic strategies for treating polyglutamine diseases.

SCA1 is thought to be caused by an expanded polyglutamine tract in an ataxin (ATXN1) protein that leads to damage and loss of Purkinje cells in the cerebellum. In addition, phosphorylation of a serine amino acid reside at position 776 (Ser776) is thought to be critical for pathogenesis. Recent research led by Dr. Harry T. Orr from the University of Minnesota showed that replacing Ser776 with a phospho-mimicking aspartic acid residue in ATXN1 with a normal polyglutamine tract seemed to elicit biochemical properties that resembled ATXN1 with an expanded polyglutamine tract.

To investigate the biological relevance of this earlier observation, Dr. Orr's group created transgenic mice that expressed different versions of ATXN1 in cerebellar Purkinje cells. "We found that a single amino acid change -- one that mimics phosphorylation at residue 776 -- converts wild type protein in a disease-causing protein. Clearly, phosphorylation is critical for this disease," explains Dr. Orr. The researchers went on to show that although the amino acid substitution caused the normal version of the protein to induce disease in cerebellar neurons, the pathogenesis did not progress to cell death.

Taken together, these results suggest that Ser776 is critical for initiating neuronal dysfunction, while an expanded polyglutamine tract is essential for neuronal death. "Obviously, the two are linked in that initiation is a prerequisite of later stages. Regardless, a treatment targeted at initiation, perhaps S776 phosphorylation, is likely to have a major impact clinically. Conversely treating just the cell death phase of the disease is unlikely to improve the neurological status of patients," concludes Dr. Orr.

The researchers include Lisa Duvick, University of Minnesota, Minneapolis, MN; Justin Barnes, University of Minnesota, Minneapolis, MN; Blake Ebner, University of Minnesota, Minneapolis, MN; Smita Agrawal, University of Minnesota, Minneapolis, MN; Michael Andresen, University of Minnesota, Minneapolis, MN; Janghoo Lim, Howard Hughes Medical Institute, Baylor College of Medicine, Houston, TX; Glenn J. Giesler, University of Minnesota, Minneapolis, MN; Huda Y. Zoghbi, Howard Hughes Medical Institute, Baylor College of Medicine, Houston, TX; and Harry T. Orr, University of Minnesota, Minneapolis, MN.


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. Lisa Duvick, Justin Barnes, Blake Ebner, Smita Agrawal, Michael Andresen, Janghoo Lim, Glenn J. Giesler, Huda Y. Zoghbi, Harry T. Orr. SCA1-like Disease in Mice Expressing Wild-Type Ataxin-1 with a Serine to Aspartic Acid Replacement at Residue 776. Neuron, 2010; 67 (6): 929-935 DOI: 10.1016/j.neuron.2010.08.022

Cite This Page:

Cell Press. "Getting off tract: Polyglutamine disease involves other regions of protein." ScienceDaily. ScienceDaily, 23 September 2010. <www.sciencedaily.com/releases/2010/09/100922121941.htm>.
Cell Press. (2010, September 23). Getting off tract: Polyglutamine disease involves other regions of protein. ScienceDaily. Retrieved January 24, 2015 from www.sciencedaily.com/releases/2010/09/100922121941.htm
Cell Press. "Getting off tract: Polyglutamine disease involves other regions of protein." ScienceDaily. www.sciencedaily.com/releases/2010/09/100922121941.htm (accessed January 24, 2015).

Share This


More From ScienceDaily



More Mind & Brain News

Saturday, January 24, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Smart Wristband to Shock Away Bad Habits

Smart Wristband to Shock Away Bad Habits

Reuters - Innovations Video Online (Jan. 23, 2015) — A Boston start-up is developing a wristband they say will help users break bad habits by jolting them with an electric shock. Ben Gruber reports. Video provided by Reuters
Powered by NewsLook.com
Amazing Technology Allows Blind Mother to See Her Newborn Son

Amazing Technology Allows Blind Mother to See Her Newborn Son

RightThisMinute (Jan. 23, 2015) — Not only is Kathy seeing her newborn son for the first time, but this is actually the first time she has ever seen a baby. Kathy and her sister, Yvonne, have been legally blind since childhood, but thanks to an amazing new technology, eSight glasses, which gives those who are legally blind the ability to see, she got the chance to see the birth of her son. It&apos;s an incredible moment and an even better story. Video provided by RightThisMinute
Powered by NewsLook.com
One Dose, Then Surgery to Test Tumor Drugs Fast

One Dose, Then Surgery to Test Tumor Drugs Fast

AP (Jan. 23, 2015) — A Phoenix hospital is experimenting with a faster way to test much needed medications for deadly brain tumors. Patients get a single dose of a potential drug, and hours later have their tumor removed to see if the drug had any affect. (Jan. 23) Video provided by AP
Powered by NewsLook.com
The Best Bedtime Rituals For a Good Night's Sleep

The Best Bedtime Rituals For a Good Night's Sleep

Buzz60 (Jan. 22, 2015) — What you do before bed can effect how well you sleep. TC Newman (@PurpleTCNewman) has bedtime rituals to induce the best night&apos;s sleep. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins